A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients

Inclusion Criteria: * Written informed consent. * Male and female subjects 18 to 65 years of age with hepatitis C infections (genotypes 1, 2 or 3). * No prior therapy or inadequate response to therapy for hepatitis C. * Weight at least 50 kg and body mass index (BMI) within 18 - 35 kg/m2. Exclusion Criteria: * Use of other investigational drugs within at least 30 days of enrollment * Women of child-bearing potential. Other protocol-defined inclusion/exclusion criteria apply